版本:
中国

BRIEF-NeuroVive Pharmaceutical enters into global licensing agreement with Yungjin Pharm

May 2 Yungjin Pharm Co Ltd:

* announced it has entered into global licensing agreement on Yungjin Pharm's compound KL1333 for genetic mitochondrial disorders

* will now initiate activities in preparation for next clinical study in Europe and/or in U.S.

* NeuroVive will pay Yungjin Pharm upfront payments of $1 million at signing

* NeuroVive will pay Yungjin Pharm additional $1 million after completion of a successful phase I clinical trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐